Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PROTHENA CORPORATION PLC

(PRTA)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-07 pm EST
57.20 USD   -1.84%
02/06Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
02/03Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
02/01Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005 a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer's Disease
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Prothena Achieves $40 Million Clinical Milestone Payment From Novo Nordisk

11/21/2022 | 04:43pm EST

By Mary de Wet


Prothena Corp. said Monday that it earned a $40 million milestone payment from Novo Nordisk A/S related to the advancement of NNC6019 in a Phase 2 clinical study for the treatment of ATTR cardiomyopathy.

The study was initiated in August and is investigating the safety and efficacy of NNC6019 in 99 people with transthyretin amyloid cardiomyopathy, a progressive disease that is often fatal.

Novo Nordisk gained worldwide rights to the intellectual property and related rights of the ATTR amyloidosis business and pipeline it acquired from Prothena in July 2021, the biotechnology company said.

Under the terms of the agreement, Prothena is eligible to receive up to $1.2 billion upon achievement of several clinical development and sales milestones, the company said. Prothena said it has received $100 million to date.


Write to Mary de Wet at mary.dewet@wsj.com


(END) Dow Jones Newswires

11-21-22 1643ET

Stocks mentioned in the article
ChangeLast1st jan.
NOVO NORDISK A/S 0.85% 966.1 Delayed Quote.2.13%
PROTHENA CORPORATION PLC -1.84% 57.195 Delayed Quote.-3.29%
All news about PROTHENA CORPORATION PLC
02/06Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
02/03Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
02/01Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005 a Novel ..
AQ
01/31Prothena Delivers 'Positive' Results From Phase 1 Study of Single-Dose Treatment for Al..
MT
01/31Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel..
BU
01/31Prothena Corporation plc Reports Topline Phase 1 Single Ascending Dose Study Results of..
CI
01/27Piper Sandler Starts Prothena at Overweight With $94 Price Target
MT
01/13RBC Lifts Price Target on Prothena to $56 From $55, Maintains Sector Perform Rating
MT
01/09Prothena : Corporate Overview
PU
2022Insider Sell: Prothena Corp Public Ltd
MT
More news
Analyst Recommendations on PROTHENA CORPORATION PLC
More recommendations
Financials (USD)
Sales 2022 43,0 M - -
Net income 2022 -140 M - -
Net Debt 2022 - - -
P/E ratio 2022 -19,5x
Yield 2022 -
Capitalization 2 953 M 2 953 M -
Capi. / Sales 2022 68,7x
Capi. / Sales 2023 61,1x
Nbr of Employees 82
Free-Float 94,2%
Chart PROTHENA CORPORATION PLC
Duration : Period :
Prothena Corporation plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTHENA CORPORATION PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 57,20 $
Average target price 84,60 $
Spread / Average Target 47,9%
EPS Revisions
Managers and Directors
Gene G. Kinney President, Chief Executive Officer & Director
Tran B. Nguyen Chief Financial & Strategy Officer
Lars G. Ekman Chairman
Wagner M. Zago Head-Research
Hideki Garren Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTHENA CORPORATION PLC-3.29%3 008
REGENERON PHARMACEUTICALS, INC.8.54%83 397
VERTEX PHARMACEUTICALS4.24%78 258
WUXI APPTEC CO., LTD.13.21%39 435
BIONTECH SE-5.43%34 256
BEIGENE, LTD.11.48%25 531